Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
A drug that blocks production of an enzyme that enables ovarian cancer to gain a foothold in a new site can slow the spread of the disease and prolong survival in mice, according to a study by researchers from the University of Chicago Medical Center, but only if the drug is given early in the disease process.
ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years.
Up to 20 percent of patients taking aspirin to lower the risk of suffering a second cerebrovascular event do not have an antiplatelet response from aspirin, the effect thought to produce the protective effect, researchers at the University at Buffalo have shown.
The finding, appearing online in the journal Circulation, is the first to document a genetic mutation linked to PAD. Although the work was done in mice, researchers say it is likely to give them new insight into how PAD develops and progresses in humans.
A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells was transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.
Physicians currently evaluate a patient's risk for heart disease, stroke and other cardiovascular diseases (CVD) individually, but a new assessment tool could gauge risk of overall 'or global' CVD and a range of cardiovascular diseases at one time, according to a study published in Circulation: Journal of the American Heart Association.
Although approved by the U.S. Food and Drug Administration as a palliative treatment for cancer patients who have developed bile-duct obstructions, biliary stents are sometimes used "off-label" for the treatment of peripheral vascular disease (PVD).
After many years of experience, and over 2400 laser eyelid rejuvenation procedures my understanding of the condition often referred to as dark circles under the eyes has evolved to, I believe, a better understanding of this common condition and a newer more effective surgical strategy for the correction of dark circles under eyes.
Nearly three-fourths of American adults with conditions such as coronary heart disease, stroke, diabetes or others that raise their risk for cardiovascular complications also have hypertension (high blood pressure), according to a report in the December 10/24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
After examining data from government health surveys undertaken in the United States, researchers say more American women are developing a type of artery disease that raises the risk of death from heart disease and stroke.
The prevalence of asymptomatic peripheral artery disease (PAD) is steadily increasing among American adults, researchers reported at the American Heart Association's Scientific Sessions 2007.
Researchers have discovered a key protein that controls how stem cells "choose" to become either skeletal muscle cells that move limbs, or smooth muscle cells that support blood vessels, according to a study published in the Proceedings of the National Academy of Sciences (PNAS).
Keck Graduate Institute (KGI) announced that Dr. Animesh Ray, KGI professor and director of KGI's PhD program, has published a paper in the international online journal PLoS ONE that sheds new light on the evolution of moveable genetic elements, or "jumping genes."
The benefits of applying technological know how to patient care were demonstrated by Prime Minister Gordon Brown at Imperial College London.
Cardiovascular Systems, Inc. (CSI) has announced that the U.S. Food and Drug Administration (FDA) has cleared the use of the Diamondback 360 Orbital Atherectomy System (OAS) for removing plaque blockages in the legs (peripherals) and restoring blood flow.
Researchers in the United States are warning that the soft cushioned bumpers used around cribs and bassinets, do more harm than good.
Although bumper pads are theoretically designed to prevent injury to a baby while in the crib or bassinet, the risk of accidental death or injury to an infant from using them outweighs their possible benefits, according to a new study by pediatric researchers at Washington University School of Medicine in St. Louis.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).
Surgeons at the Methodist DeBakey Heart Center in Houston were among the first in the U.S. to implant a new, less-invasive stent graft designed to reduce the risk of blood clots in patients treated for peripheral arterial disease (PAD), which affects as many as 12 million Americans over the age of 50.
Patients with atherosclerosis in the leg arteries face a substantially increased all-cause and cardiovascular mortality risk, according to a large study presented at the European Society of Cardiology Congress in Vienna.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.